Biotech company Propanc may receive up to $100 million in financing to build crypto asset portfolio and develop cancer treatments

According to Foresight News, The Block reported that Australian biopharmaceutical company Propanc Biopharma (stock code PPCB) may receive up to $100 million in financing from family office Hexstone Capital. The private financing, structured as a convertible preferred stock, will see Propanc receive an initial investment of $1 million and follow-on funding of up to $99 million over the next year. The funds will be used to build the company’s crypto asset portfolio and accelerate the development of its lead oncology therapy, PRP, which is scheduled for first-in-human trials in 2026.
Disclaimer: The views in this article only represent the author's personal views and do not constitute investment advice from this platform. This platform does not make any guarantees about the accuracy, completeness, originality and timeliness of the information in the article, nor is it responsible for any losses caused by the use or reliance of the information in the article.